DeepMed Research

Surufatinib

Generic Name: Surufatinib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Clinical Trials

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Phase 2

Conditions: Head and Neck Cancers - Salivary Gland

First Posted Date: 2021-06-02

Last Posted Date: 2021-06-02

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 27

Registration Number: NCT04910854

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Expanded Access Program of Surufatinib

Conditions: Neuroendocrine Tumors

First Posted Date: 2021-03-24

Last Posted Date: 2024-04-12

Lead Sponsor: Hutchmed

Registration Number: NCT04814732

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 8 locations

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Phase 2

Conditions: Advanced Colorectal Cancer

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-21

Last Posted Date: 2021-11-04

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 10

Registration Number: NCT04764006

Locations: 🇨🇳
China, Fujian, Fuzhou, Fujian, China

Surufatinib Hepatic Impairment Study

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-15

Last Posted Date: 2022-08-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 16

Registration Number: NCT04755075

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States

Surufatinib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-15

Last Posted Date: 2022-11-03

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 16

Registration Number: NCT04755088

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Surufatinib
Drug: Toripalimab
Drug: chemotherapy

First Posted Date: 2020-12-04

Last Posted Date: 2023-07-17

Lead Sponsor: Zhejiang University

Target Recruit Count: 61

Registration Number: NCT04653480

Locations: 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Open-Label Surufatinib in European Patients with NET

Phase 2

Completed

Conditions: Neuroendocrine Tumours
Neuroendocrine Tumour of the Lung
Small Intestinal NET

Interventions: Drug: Surufatinib

First Posted Date: 2020-10-08

Last Posted Date: 2025-03-20

Lead Sponsor: Hutchmed

Target Recruit Count: 78

Registration Number: NCT04579679

Locations: 🇺🇸
Houston Methodist, Hosuton, Texas, United States
🇫🇷
CHU Bordeaux, Pessac, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 20 locations

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neuroendocrine Tumors
Small Cell Lung Cancer
Metastatic Solid Tumor
Colorectal Cancer
Soft Tissue Sarcoma
Anaplastic Thyroid Cancer
Gastric Cancer

Interventions: Drug: Surufatinib and Tislelizumab _ Part 1
Drug: Surufatinib and Tislelizumab _ Part 2

First Posted Date: 2020-10-08

Last Posted Date: 2025-05-08

Lead Sponsor: Hutchmed

Target Recruit Count: 87

Registration Number: NCT04579757

Locations: 🇺🇸
Arizona Oncology Associated, PC-HOPE, Tucson, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Johns Hopkins University - Sibley Memorial Hospital, Washington, District of Columbia, United States

and more 14 locations

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Phase 2

Conditions: Thyroid Cancer

Interventions: Drug: Surufatinib
Drug: Toripalimab

First Posted Date: 2020-08-24

Last Posted Date: 2020-08-24

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT04524884

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: Surufatinib plus Sintilimab

First Posted Date: 2020-06-11

Last Posted Date: 2021-07-20

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 8

Registration Number: NCT04427774

Locations: 🇨🇳
Jiangsu Province, Nanjing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy